Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-04-02
2009-08-04
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252180, C514S275000, C544S122000, C544S295000, C544S331000
Reexamination Certificate
active
07569566
ABSTRACT:
The invention relates to compounds of formulawherein the substituents R1, R2 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, especially a neoplastic disease, in particular leukaemia, and a method for the treatment of such a disease.
REFERENCES:
patent: 5516775 (1996-05-01), Zimmermann et al.
patent: 5521184 (1996-05-01), Zimmermann
patent: 2006/0014742 (2006-01-01), Asaki et al.
patent: 0 588 762 (1994-03-01), None
patent: 6-184116 (1994-07-01), None
patent: 95/09853 (1995-04-01), None
patent: 02/46170 (2002-06-01), None
patent: 02/46171 (2002-06-01), None
patent: 2004/002963 (2004-01-01), None
Zimmermann et al., “Potent and Selective Inhibitors of the ABL-Kinase: Phenylamino-Pyrimidine (PAP) Derivatives,” Bioorganic & Medical Chemistry Letters, vol. 7, No. 2, pp. 187-192 (1997).
Zimmermann et al., “Phenylamino-Pyrimidine (PAP)—Derivatives: A New Class of Potent and Highly Selective PDGF-Receptor Autophosphorylatin Inhibitors,” Bioorganic & Medicinal Chemistry Letters, vol. 6, No. 11, pp. 1221-1226 (1996).
Paul et al., “Preparation of Substituted N-Phenyl-4-aryl-2-pyrimidinamines as Mediator Release Inhibitors,” J. Med. Chem., vol. 36, pp. 2716-2725 (1993).
Bhat et al., “Interactions of CBL with BCR-ABL and CRKL in BCR-ABL transformed Myeloid Cells,” The Journal of Biological Chemistry, vol. 272, No. 26, Issue of Jun. 27, pp. 16170-16175 (1997).
Shibuya et al., “Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (fit) closely related to thefmsfamily,” Oncogene, vol. 5, pp. 519-524 (1990).
Dorsey et al., “Discovery of a Novel ABL Tyrosine Kinase Inhibitor That Selectively Induces Apoptosis of BCR-ABL-Positive Leukemic Cells,” Abstracts/Hematology, vol. 28(7), Suppl. 1, p. 49 (2000).
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20thEdition, vol. 1, pp. 1004-1010 (1996).
Traxler, “Protein tyrosine kinase inhibitors in cancer treatment,” Exp. Opin. Ther. Patents, 7(6):571-588 (1997).
Breitenstein Werner
Furet Pascal
Jacob Sandra
Manley Paul W
McNally Lydia T.
Novartis AG
Rao Deepak
LandOfFree
Inhibitors of tyrosine kinases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of tyrosine kinases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of tyrosine kinases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4119469